Fig. 1: Reduction of Usp18 delays cancer progression.
From: Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis
a Representative pictures of embryos (E14.5) of Usp18+/+, Usp18+/−, and Usp18−/− (Top) and Usp18f/f, Usp18+/f Vav-iCre, and Usp18f/f Vav-iCre (Bottom) mice. b Western blots showing phosphorylated and total STAT1 protein and β-actin in Usp18 WT and Heterozygous bone marrows. c Ratio of live cells from Usp18+/Δ BMDM or Usp18+/Δ AE9a cells treated with different doses of IFNβ for 72 h in one representative set of three independent repeats. p-value was determined by one-way ANOVA test. (Usp18+/Δ BMDM n = 3, Usp18+/Δ AE9a n = 3). d Percentage of Annexin V+ GFP+Lin−c-Kit+ splenocytes from Usp18+/f and Usp18+/Δ AE9a recipient mice as analyzed by FACS. p-value was determined by two-tailed Student t-test. (Usp18+/f n = 6 mice, Usp18+/Δ n = 6 mice). e Absolute numbers of CD8+, activated T cells (CD8+/CD69+, CD8+/CD25+, CD8+/CD71+), Tregs (CD4+CD25+Foxp3+) and B cells (CD19+) in viable host splenocytes per 10,000 GFP+ cells from Usp18+/f and Usp18+/Δ AE9a recipient mice. Information on other immune cell populations is also shown in source data. P-value was determined by two-tailed Student t-test. (Usp18+/f n = 7 mice, Usp18+/Δ n = 5 mice). f Kaplan–Meier survival curve for recipients of Usp18+/f or +/Δ UBCER-Cre AE9a-GFP AMLs. p-value was determined by log-rank test. (Usp18+/f n = 6 mice, Usp18+/Δ n = 6 mice). g Percentage of GFP+ cells in the PB of mice from (f). p-value was determined by one-way ANOVA test. h Timeline of treatments combining chemotherapy with heterozygous deletion of Usp18 to treat AML. i Kaplan–Meier survival curve for mice treated as in (h). (Oil (+/f) n = 6 mice, Tam (+/Δ) n = 4 mice). p-value was determined by log-rank test. j Percentage of GFP+ cells in the PB of mice from (i), analyzed weekly by FACS. All data represent mean ± s.d, except where indicated. n.s. = not statistically significant. Source data are provided as a Source Data file.
